Procter & Gamble Health Ltd
Procter & Gamble Health Ltd (PGHL) is scheduled to report results on 2 Nov 2026. Procter & Gamble Health Ltd last reported results for the quarter ended Jun 2026, with sales of ₹364 crore and net profit of ₹96 crore. The stock last traded at ₹5,205, a market capitalisation of ₹8,638 crore, on a P/E of 25.9. Over the past 52 weeks the stock has ranged between ₹4,700 and ₹6,975. Figures are as of 9 Oct 2026 and are not real time.
Procter & Gamble Health Ltd share price and key metrics
- Current price
- ₹5,205
- Market cap
- ₹8,638 cr
- Stock P/E
- 25.9
- Book value
- ₹316
- ROE
- 61.9%
- ROCE
- 83.9%
- Dividend yield
- 2.98%
- 52w high / low
- 6975/4700
Metrics as of 9 Oct 2026. Not real time.
Track Procter & Gamble Health Ltd
Cruxal reads every Procter & Gamble Health Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Procter & Gamble Health Ltd growth and returns
- 10 Years
- 4%
- 5 Years
- 1%
- 3 Years
- 8%
- TTM
- 13%
- 10 Years
- 20%
- 5 Years
- 5%
- 3 Years
- 19%
- TTM
- 11%
- 10 Years
- 22%
- 5 Years
- -2%
- 3 Years
- 1%
- 1 Year
- -14%
- 10 Years
- 31%
- 5 Years
- 35%
- 3 Years
- 43%
- Last Year
- 62%
Procter & Gamble Health Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹364 cr, up 7.4% from ₹339 cr a year earlier. Net profit was ₹96 cr, up 45.5% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 313 | 310 | 311 | 339 | 325 | 374 | 370 | 364 |
| Expenses | 199 | 186 | 230 | 248 | 205 | 263 | 235 | 264 |
| Operating profit | 114 | 123 | 81 | 90 | 120 | 110 | 136 | 100 |
| OPM % | 36% | 40% | 26% | 27% | 37% | 30% | 37% | 27% |
| Other income | 3 | 4 | 3 | 4 | 5 | 4 | 4 | 36 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 6 | 6 | 5 | 5 | 6 | 6 | 6 | 6 |
| Profit before tax | 111 | 122 | 79 | 89 | 119 | 109 | 133 | 129 |
| Tax % | 26% | 25% | 22% | 25% | 26% | 29% | 29% | 26% |
| Net profit | 82 | 91 | 61 | 66 | 89 | 78 | 95 | 96 |
| EPS (₹) | 49.60 | 54.76 | 36.86 | 39.87 | 53.34 | 46.74 | 56.99 | 57.92 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Procter & Gamble Health Ltd annual results
| ₹ crore | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 940 | 993 | 698 | 849 | 927 | 1,009 | 1,114 | 1,230 | 1,151 | 1,408 | 1,433 |
| Operating profit | 85 | 116 | 77 | 148 | 204 | 246 | 268 | 325 | 307 | 459 | 466 |
| OPM % | 9% | 12% | 11% | 17% | 22% | 24% | 24% | 26% | 27% | 33% | 33% |
| Net profit | 54 | 79 | 94 | 839 | 159 | 177 | 193 | 229 | 201 | 327 | 357 |
| EPS (₹) | 32.27 | 47.67 | 56.57 | 505.27 | 95.64 | 106.51 | 115.98 | 138.24 | 121.08 | 196.94 | 214.99 |
TTM is the trailing twelve months to the most recent quarter.
Procter & Gamble Health Ltd balance sheet
| ₹ crore | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 717 | 1,524 | 800 | 890 | 687 | 600 | 734 | 522 | 520 | 508 |
| Borrowings | 0 | 0 | 0 | 0 | 8 | 3 | 12 | 10 | 8 | 9 |
| Other liabilities | 258 | 219 | 250 | 269 | 275 | 269 | 338 | 247 | 250 | 308 |
| Total liabilities | 991 | 1,759 | 1,067 | 1,176 | 986 | 888 | 1,101 | 794 | 794 | 841 |
| Fixed assets | 115 | 104 | 101 | 101 | 104 | 112 | 144 | 128 | 116 | 102 |
| CWIP | 9 | 17 | 11 | 21 | 39 | 41 | 32 | 6 | 11 | 14 |
| Investments | 70 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 797 | 1,639 | 954 | 1,053 | 843 | 736 | 925 | 660 | 667 | 726 |
| Total assets | 991 | 1,759 | 1,067 | 1,176 | 986 | 888 | 1,101 | 794 | 794 | 841 |
As reported by the company. Total assets equal total liabilities by construction.
Procter & Gamble Health Ltd cash flow
| ₹ crore | Dec 2017 | Dec 2018 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 54 | -130 | 235 | 247 | 170 | 236 | 228 | 169 | 338 |
| Cash from investing | -48 | 1,270 | 165 | -32 | -26 | -22 | -7 | 10 | 1 |
| Cash from financing | -22 | -30 | -883 | -387 | -289 | -98 | -418 | -235 | -344 |
| Net cash flow | -16 | 1,109 | -483 | -172 | -145 | 116 | -197 | -56 | -5 |
| Free cash flow | 24 | -157 | 212 | 196 | 132 | 198 | 207 | 168 | 323 |
| CFO / operating profit | 147% | 117% | 106% | 128% | 87% | 100% | 102% | 78% | 96% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Procter & Gamble Health Ltd operating ratios
| Per year | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 16% | 78% | 20% | 29% | 29% | 38% | 45% | 45% | 48% | 84% |
| Debtor days | 64 | 28 | 30 | 26 | 22 | 27 | 34 | 27 | 57 | 43 |
| Inventory days | 243 | 154 | 139 | 113 | 138 | 124 | 136 | 120 | 152 | 137 |
| Days payable | 128 | 124 | 106 | 105 | 209 | 185 | 239 | 184 | 239 | 192 |
| Cash conversion cycle | 179 | 58 | 63 | 34 | -49 | -34 | -69 | -37 | -30 | -13 |
| Working capital days | 94 | 42 | 22 | 23 | 7 | 17 | 15 | 19 | 48 | 30 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Procter & Gamble Health Ltd shareholding pattern
Promoters held 51.82% at Jun 2026, broadly unchanged since Jun 2025. FIIs 6.33% and DIIs 12.44%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% |
| FIIs | 6.61% | 7.01% | 6.86% | 6.99% | 7.24% | 6.97% | 6.20% | 6.33% |
| DIIs | 14.84% | 14.71% | 14.21% | 14.15% | 13.90% | 13.84% | 13.67% | 12.44% |
| Public | 26.74% | 26.47% | 27.11% | 27.03% | 27.05% | 27.37% | 28.30% | 29.41% |
| No. of shareholders | 54,792 | 53,736 | 53,993 | 52,478 | 50,006 | 49,302 | 50,883 | 49,056 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Procter & Gamble Health Ltd’s next results date?
Procter & Gamble Health Ltd’s next results are scheduled for 2 Nov 2026.
- Board meetingConsideration and approval of unaudited financial results for Q2 and H1 ended September 30, 2026
See the full results calendar for every Indian company reporting in the next 30 days.
Procter & Gamble Health Ltd corporate filings
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Company Updatelow impact
Cruxal's analysis: Please find attached signed Certifiacte for confirming compliance under Regulation 74(5)…
Read the full analysis - Procter & Gamble Health scheduled to announce Q2 FY2027 unaudited financial results on November 2, 2026, with no specific financial figures disclosed in the filing.Board Meetinghigh impact
Cruxal's analysis: Procter & Gamble Health Limited has intimated a board meeting on November 2, 2026, to…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.